Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

NCT03331198 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Small Lymphocytic

Interventions

BIOLOGICAL: JCAR017 (lisocabtagene maraleucel)
BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) + ibrutinib
BIOLOGICAL: JCAR017 (lisocabtagene maraleucel) + venetoclax

Sponsor

Juno Therapeutics, a Subsidiary of Celgene